Generation and formatting of Affimer® affinity binders for the inhibition of the PD-L1/PD-1 pathway

Abstract

Affimer reagents and therapeutics are a class of non-antibody binding proteins that have been engineered for a wide range of applications where antibodies and aptamers have limitations. They are produced without the use of animals, can be used to detect difficult targets, can easily be formatted for a wide range of applications and can be easily and cost effectively manufactured. Using phage display, we have identified competitive binders to a range of targets, including the immune check point, Programmed death-ligand 1 (PD-L1). PD-L1 plays an important role in immune homeostasis and blockade of the PD-L1/ PD-1 pathway using antibodies has demonstrated impressive anti-tumour responses in cancer patients. Our inhibitors have been shown to be highly selective for PD-L1 with KD’s of single digit nM as determined by BIAcore. We have shown that the scaffold is amenable to being engineered to make multimers (dimers, trimers and tetramers) as well as being formatted to extend the serum half-life. 1000

Cite this paper

@inproceedings{Miller2017GenerationAF, title={Generation and formatting of Affimer® affinity binders for the inhibition of the PD-L1/PD-1 pathway}, author={C. L. Miller and Emma Jenkins and Estelle Adam and Anna Ah-San Tang and Andrew Wilcox and Christina Rauber and Lindsay Mcmorran and Matt W. Johnson and Amrik Basran and Kelly R Stevens and Adrian Smith and Eddie R Clutton and Elliot J. Lilley and Kristine E Aa Hansen and Trond Brattelid}, year={2017} }